In contrast, the inhibition of NF-κB by the small molecule inhibitor BAY 11-7082 or by siRNA-mediated gene silencing reduced MGMT levels and thereby sensitized glioma stem-like cells to TMZ treatment [30,32]. The gene discussed is NFKB1; the disease is central nervous system cancer.